Dr Benjamin Elyan
- Clinical Research Fellow (Cardiovascular & Metabolic Health)
Research interests
Research Theme: Cardiovascular Data Science
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Research Theme: Cardiovascular Data Science
Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010)
Shemilt, R. et al. (2024) Sex differences in cancer outcomes across the range of eGFR. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfae059) (PMID:38460949) (Early Online Publication)
Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Lees, J. S. , Dobbin, S. J.H. , Elyan, B. M.P., Gilmour, D. F., Tomlinson, L. P., Lang, N. N. and Mark, P. B. (2023) A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation, 38(7), pp. 1666-1681. (doi: 10.1093/ndt/gfac305) (PMID:36318455) (PMCID:PMC10310520)
Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010)
Shemilt, R. et al. (2024) Sex differences in cancer outcomes across the range of eGFR. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfae059) (PMID:38460949) (Early Online Publication)
Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Lees, J. S. , Dobbin, S. J.H. , Elyan, B. M.P., Gilmour, D. F., Tomlinson, L. P., Lang, N. N. and Mark, P. B. (2023) A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation, 38(7), pp. 1666-1681. (doi: 10.1093/ndt/gfac305) (PMID:36318455) (PMCID:PMC10310520)